In the previous study, a significant downregulation of miR-139 expression was observed in clinical HCC tissues, and miR-139 functions as an anticancer gene and suppresses the β-catenin/TCF-4 transcriptional activity by targeting TCF-4 (Gu et al., 2014). Here, TCF4 is linked to hepatocellular carcinoma.